STOCK TITAN

Endo to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Endo (OTCQX: NDOI) has announced it will release its fourth quarter and full year 2024 financial results on March 11, 2025, before the market opens. The company will host a conference call at 8:00 a.m. ET on the same day.

Investors can access the audio webcast through the Investor Relations section of Endo's website at investor.endo.com under Events & Presentations. Conference call participants can dial 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (international). Participants should join 10 minutes before the scheduled start time. A webcast replay will be available after the event.

Endo (OTCQX: NDOI) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 il 11 marzo 2025, prima dell'apertura del mercato. L'azienda ospiterà una conference call alle 8:00 a.m. ET lo stesso giorno.

Gli investitori possono accedere alla trasmissione audio tramite la sezione Relazioni con gli Investitori del sito web di Endo all'indirizzo investor.endo.com sotto Eventi e Presentazioni. I partecipanti alla conference call possono comporre il numero 800-836-8184 (numero verde per Stati Uniti e Canada) o 646-357-8785 (internazionale). I partecipanti dovrebbero unirsi 10 minuti prima dell'orario di inizio programmato. Una registrazione della trasmissione sarà disponibile dopo l'evento.

Endo (OTCQX: NDOI) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 11 de marzo de 2025, antes de la apertura del mercado. La compañía realizará una llamada de conferencia a las 8:00 a.m. ET el mismo día.

Los inversores pueden acceder a la transmisión de audio a través de la sección de Relaciones con Inversores del sitio web de Endo en investor.endo.com en Eventos y Presentaciones. Los participantes de la llamada de conferencia pueden marcar 800-836-8184 (número gratuito para EE. UU. y Canadá) o 646-357-8785 (internacional). Los participantes deben unirse 10 minutos antes de la hora de inicio programada. Una repetición de la transmisión estará disponible después del evento.

Endo (OTCQX: NDOI)는 2024년 4분기 및 연간 재무 결과2025년 3월 11일에 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8:00 ET에 컨퍼런스 콜을 개최할 예정입니다.

투자자들은 Endo 웹사이트의 투자자 관계 섹션인 investor.endo.com의 이벤트 및 프레젠테이션에서 오디오 웹캐스트에 액세스할 수 있습니다. 컨퍼런스 콜 참가자는 800-836-8184 (미국 및 캐나다 무료전화) 또는 646-357-8785 (국제전화)로 전화할 수 있습니다. 참가자는 예정된 시작 시간 10분 전에 접속해야 합니다. 이벤트 후에는 웹캐스트 재생이 가능합니다.

Endo (OTCQX: NDOI) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le 11 mars 2025, avant l'ouverture du marché. La société organisera une conférence téléphonique à 8h00 ET le même jour.

Les investisseurs peuvent accéder au webinaire audio via la section Relations Investisseurs du site d'Endo à l'adresse investor.endo.com sous Événements et Présentations. Les participants à la conférence téléphonique peuvent composer le 800-836-8184 (numéro gratuit pour les États-Unis et le Canada) ou le 646-357-8785 (international). Les participants doivent se connecter 10 minutes avant l'heure de début prévue. Une rediffusion du webinaire sera disponible après l'événement.

Endo (OTCQX: NDOI) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am 11. März 2025 vor der Markteröffnung veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz abhalten.

Investoren können über den Bereich Investor Relations auf der Website von Endo unter investor.endo.com auf das Audio-Webcast zugreifen, der unter Veranstaltungen & Präsentationen zu finden ist. Teilnehmer der Telefonkonferenz können die Nummer 800-836-8184 (gebührenfrei für die USA und Kanada) oder 646-357-8785 (international) wählen. Die Teilnehmer sollten 10 Minuten vor dem geplanten Beginn beitreten. Eine Wiederholung des Webcasts wird nach der Veranstaltung verfügbar sein.

Positive
  • None.
Negative
  • None.

MALVERN, Pa., Feb. 21, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it will report fourth quarter and full year 2024 financial results on March 11, 2025, prior to market open. The Company will host a conference call on the same day at 8:00 a.m. ET.

The audio webcast may be accessed through the Investor Relations section of the Company's website at investor.endo.com under Events & Presentations. To access the call through a conference line, participants may dial 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (outside the U.S.). Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event.

About Endo
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-302382020.html

SOURCE Endo, Inc.

FAQ

When will Endo (NDOI) release its Q4 and full year 2024 earnings?

Endo will release its Q4 and full year 2024 financial results on March 11, 2025, before market open.

What time is Endo's Q4 2024 earnings conference call?

Endo's Q4 2024 earnings conference call is scheduled for March 11, 2025, at 8:00 a.m. ET.

How can investors access Endo's Q4 2024 earnings call?

Investors can access the audio webcast through investor.endo.com under Events & Presentations, or dial 800-836-8184 (U.S./Canada) or 646-357-8785 (international).

Will there be a replay available of Endo's Q4 2024 earnings call?

Yes, a replay of the webcast will be available following the event.

Endo Inc

OTC:NDOI

NDOI Rankings

NDOI Latest News

NDOI Stock Data

2.00B
67.50M
55.62%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Malvern